Quality & complianceOfficial

Denmark flags supply problems with Perrigo's NorLevo emergency contraceptive tablets

🇩🇰 DKMA · Fri 13 Nov 2026

The Danish Medicines Agency says production problems at Perrigo Sverige AB are affecting supply of NorLevo 1.5 mg levonorgestrel tablets, with the expected period running from early to mid-November 2026.

The Danish Medicines Agency (DKMA) has published a supply notice on NorLevo 1.5 mg tablets, saying there are current problems with availability of the product from Perrigo Sverige AB. The notice is dated 13 November 2026.

NorLevo contains levonorgestrel, an emergency contraceptive, and carries ATC code G03AD01. DKMA gives production problems as the cause of the difficulty.

The agency lists the expected period of the disruption as from the start of November to mid-November 2026. The notice does not say whether supply has been restored, nor does it name alternative products or describe any measures to bridge the gap.

DKMA refers questions about the current status to the company. The notice sits in the agency's section on supply notices for human medicines.

What it means for your team

  • Supply-chain and QA teams with Danish exposure should check current NorLevo availability directly with Perrigo, as DKMA points enquiries to the company.
  • The notice gives no information on alternatives or on whether the shortfall has ended, so contingency planning rests on information from the marketing authorisation holder.
  • Teams tracking supply notices should note that DKMA cites production problems as the cause, with an expected period of early to mid-November 2026.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →